echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > East Sunshine: Rivaroxaban tablets obtained drug registration certificate

    East Sunshine: Rivaroxaban tablets obtained drug registration certificate

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 26, Guangdong Dongyang Sunshine Technology Holdings Co.


    Rivaroxaban is an anticoagulant drug used in adult patients with elective hip or knee replacement surgery to prevent venous thrombosis (VTE); or to treat adult venous thrombosis (DVT) to reduce the recurrence of DVT after acute DVT And the risk of pulmonary embolism (PE); or for those with one or more risk factors (for example: congestive heart failure, hypertension, age ≥75 years, diabetes, stroke or transient ischemic attack history) Adult patients with valvular atrial fibrillation to reduce the risk of stroke and systemic embolism.


    Rivaroxaban is a category B product in the 2020 edition of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog, and it is also a category in the 2018 edition of the National Essential Drug List.


    The product is Rivaroxaban tablets, one of 27 generic drugs purchased by the company's holding subsidiary, Yichang Dongguang Yangtze Pharmaceutical Co.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.